ROUND 1

ASSESSMENT Put zen in your presentations

06/05/2023
Instruction

1. Follow the below color order

2. Use proper layout
3. We expect good design and 100% accuracy in all slides
4. Each slide should be fixed/designed based on instructions in each slide (yellow sticker)
5. Slides do not require any other images other than what is given in the deck
6. We expect all the slides to be visually enhanced

LET US KNOW IF YOU HAVE ANY QUERIES….

Default Font Color Order

Arial

2
 PHARMACOMETRICS
Pharmacometrics Platform
Working Group
September 14, 2022

3
1 Method 1 6 RSA Event Execution

Outcomes messaging framework( subset: CX Campaign Execution

2 Portfolio simplification, brand refresh, VEF, 7
customer stories, etc ) (security)

3 Security Services 8 Customer Journey Framework

4 CL EMEA – Event Execution 9 CX Campaign execution( BCS)

Transform infrastructure
5 10 Success Tracks (Partner)
integration
 Agenda

Review current Discuss

state Voluma acceleration Discuss best
Temple plan, opportunities and practices for
identify critical levers for Voluma document review
path Temple

Agenda: 1 Agenda: 2 Agenda: 3

10:30 -11:00 A.M 11:00 -11:30 A.M 11:30 -11:50 A.M

5
Of the oncologists aware of CLDN18.2, half have seen clinical trials pertaining
to the biomarker, while an additional 18% have themselves used it in trials

Level of knowledge of emerging biomarkers

CLDN 18.2 Perception

USA| Oncologists | Jun 22

Academic Community

By name only 5 5
6 18
Seen clinical data 10
10 8
pertaining to biomarker
Involved in clinical trials 17
2 4 31 9
using biomarker

Q12. Which of the following best describes your level of knowledge or experience with each of the following emerging biomarkers? FGFR2b CLDN18.2 6
 Milestones 2022

SEP SEP OCT OCT NOV NOV DEC DEC

Nov 11 Dec 5
Sep 15 -25 Oct 14 Validation Testing
Requirements End User Training
Development &
Workshop Unit test
Sep 30 Dec 9
Design Go Live
Nov 18 – 22
Oct 24 Procedural
User Acceptance Documents
Testing 7